• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Lai Goldman Myla was granted 1,071 shares, increasing direct ownership by 6% to 19,424 units (SEC Form 4)

    5/8/25 4:42:06 PM ET
    $WST
    Medical/Dental Instruments
    Health Care
    Get the next $WST alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    LAI GOLDMAN MYLA

    (Last) (First) (Middle)
    530 HERMAN O. WEST DRIVE

    (Street)
    EXTON PA 19341

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    WEST PHARMACEUTICAL SERVICES INC [ WST ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/06/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/06/2025 A 1,071(1) A $0 19,423.93 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.
    /s/ Louis Lalli, as an agent for Myla Lai Goldman 05/08/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $WST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WST

    DatePrice TargetRatingAnalyst
    3/18/2025$275.00Outperform
    Evercore ISI
    2/14/2025$250.00Hold → Buy
    Deutsche Bank
    1/8/2025$400.00Buy
    Citigroup
    12/13/2024Peer Perform
    Wolfe Research
    12/12/2024$350.00 → $390.00Neutral → Buy
    UBS
    2/7/2024$323.00 → $536.00Hold → Buy
    Jefferies
    6/16/2023$390.00 → $405.00Neutral → Buy
    BofA Securities
    4/11/2023$330.00 → $400.00Equal-Weight → Overweight
    Stephens
    More analyst ratings

    $WST
    SEC Filings

    See more
    • West Pharmaceutical Services Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      5/8/25 4:46:47 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by West Pharmaceutical Services Inc.

      10-Q - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      4/24/25 4:19:45 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      4/24/25 7:56:20 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Financials

    Live finance-specific insights

    See more
    • West Announces Leadership Changes

      Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession planning process. Bernard J. Birkett, Senior Vice President, Chief Financial Officer, informed West of his intention to step down from his current position this ye

      4/24/25 6:10:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces First-Quarter 2025 Results, Increases Adjusted-Diluted EPS Guidance and Declares Third-Quarter 2025 Dividend

      - Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the first-quarter 2025 and declared a third-quarter 2025 dividend. First-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $698.0 million increased 0.4%; organic net sales growth was 2.1%.Reported-diluted EPS of $1.23, compared to $1.55 in the same period last year.Adjusted-diluted EPS of $1.45, compared to $1.56 in the same period last year.The Company is increasing its full yea

      4/24/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West to Host First-Quarter 2025 Conference Call

      EXTON, Pa., April 10, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter financial results before the market opens on Thursday, April 24, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone particip

      4/10/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • West to Participate in Upcoming Investor Conferences

      EXTON, Pa., May 7, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the BofA Securities Annual Healthcare Conference on Wednesday, May 14, 2025 at 2:20 PM PT. It will also present at the William Blair 45th Annual Growth Stock Conference on Thursday, June 5, 2025 at 10:40 AM CT. A live audio webcast of these events will be available in the "Investors" section of the Company's website at www.westpharma.com. Replay of the webcasts will be availabl

      5/7/25 4:30:00 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces Leadership Changes

      Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession planning process. Bernard J. Birkett, Senior Vice President, Chief Financial Officer, informed West of his intention to step down from his current position this ye

      4/24/25 6:10:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces First-Quarter 2025 Results, Increases Adjusted-Diluted EPS Guidance and Declares Third-Quarter 2025 Dividend

      - Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the first-quarter 2025 and declared a third-quarter 2025 dividend. First-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $698.0 million increased 0.4%; organic net sales growth was 2.1%.Reported-diluted EPS of $1.23, compared to $1.55 in the same period last year.Adjusted-diluted EPS of $1.45, compared to $1.56 in the same period last year.The Company is increasing its full yea

      4/24/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/13/24 5:17:38 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/14/23 12:37:59 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/10/22 8:47:14 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $WST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Director Michels Douglas A was granted 1,071 shares, increasing direct ownership by 2% to 45,171 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 5:04:01 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Pucci Paolo was granted 1,071 shares, increasing direct ownership by 11% to 10,947 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 5:00:01 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Haugen Janet Brutschea was granted 1,071 shares, increasing direct ownership by 433% to 1,318 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 4:54:17 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Evercore ISI initiated coverage on West Pharm with a new price target

      Evercore ISI initiated coverage of West Pharm with a rating of Outperform and set a new price target of $275.00

      3/18/25 7:58:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharm upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded West Pharm from Hold to Buy and set a new price target of $250.00

      2/14/25 7:09:40 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Citigroup initiated coverage on West Pharm with a new price target

      Citigroup initiated coverage of West Pharm with a rating of Buy and set a new price target of $400.00

      1/8/25 8:35:06 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Leadership Updates

    Live Leadership Updates

    See more
    • Sotera Health Appoints Karen Flynn to Board of Directors

      CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

      11/13/23 7:00:14 AM ET
      $CTLT
      $QTRX
      $SHC
      $WST
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • West Announces Executive Leadership Appointments

      EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.

      5/12/22 4:30:00 PM ET
      $WST
      Medical/Dental Instruments
      Health Care